← Evidence map

ReviewPharmacoEconomics2017

Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Iñigo Bermejo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2017

this papercites it

Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. | OpenQuestion